These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18665579)

  • 1. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.
    Degnan AP; Chaturvedula PV; Conway CM; Cook DA; Davis CD; Denton R; Han X; Macci R; Mathias NR; Moench P; Pin SS; Ren SX; Schartman R; Signor LJ; Thalody G; Widmann KA; Xu C; Macor JE; Dubowchik GM
    J Med Chem; 2008 Aug; 51(16):4858-61. PubMed ID: 18665579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.
    Chaturvedula PV; Mercer SE; Pin SS; Thalody G; Xu C; Conway CM; Keavy D; Signor L; Cantor GH; Mathias N; Moench P; Denton R; Macci R; Schartman R; Whiterock V; Davis C; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3157-61. PubMed ID: 23632269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
    Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
    J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974).
    Paone DV; Shaw AW; Nguyen DN; Burgey CS; Deng JZ; Kane SA; Koblan KS; Salvatore CA; Mosser SD; Johnston VK; Wong BK; Miller-Stein CM; Hershey JC; Graham SL; Vacca JP; Williams TM
    J Med Chem; 2007 Nov; 50(23):5564-7. PubMed ID: 17929795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine.
    Rudolf K; Eberlein W; Engel W; Pieper H; Entzeroth M; Hallermayer G; Doods H
    J Med Chem; 2005 Sep; 48(19):5921-31. PubMed ID: 16161996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability.
    Degnan AP; Conway CM; Dalterio RA; Macci R; Mercer SE; Schartman R; Xu C; Dubowchik GM; Macor JE
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3555-8. PubMed ID: 19467597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Drug Discovery of
    Bucknell SJ; Ator MA; Brown AJH; Brown J; Cansfield AD; Cansfield JE; Christopher JA; Congreve M; Cseke G; Deflorian F; Jones CR; Mason JS; O'Brien MA; Ott GR; Pickworth M; Southall SM
    J Med Chem; 2020 Jul; 63(14):7906-7920. PubMed ID: 32558564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.
    Han X; Civiello RL; Conway CM; Cook DA; Davis CD; Degnan AP; Jiang XJ; Macci R; Mathias NR; Moench P; Pin SS; Schartman R; Signor LJ; Thalody G; Tora G; Whiterock V; Xu C; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1870-3. PubMed ID: 23402880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.
    Han X; Civiello RL; Conway CM; Cook DA; Davis CD; Macci R; Pin SS; Ren SX; Schartman R; Signor LJ; Thalody G; Widmann KA; Xu C; Chaturvedula PV; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4723-7. PubMed ID: 22727645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.
    Bell IM; Stump CA; Gallicchio SN; Staas DD; Zartman CB; Moore EL; Sain N; Urban M; Bruno JG; Calamari A; Kemmerer AL; Mosser SD; Fandozzi C; White RB; Zrada MM; Selnick HG; Graham SL; Vacca JP; Kane SA; Salvatore CA
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3941-5. PubMed ID: 22607672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.
    Luo G; Chen L; Conway CM; Denton R; Keavy D; Signor L; Kostich W; Lentz KA; Santone KS; Schartman R; Browning M; Tong G; Houston JG; Dubowchik GM; Macor JE
    J Med Chem; 2012 Dec; 55(23):10644-51. PubMed ID: 23153230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines.
    Civiello RL; Han X; Beno BR; Chaturvedula PV; Herbst JJ; Xu C; Conway CM; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1229-32. PubMed ID: 26832218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caprolactams as potent CGRP receptor antagonists for the treatment of migraine.
    Shaw AW; Paone DV; Nguyen DN; Stump CA; Burgey CS; Mosser SD; Salvatore CA; Rutledge RZ; Kane SA; Koblan KS; Graham SL; Vacca JP; Williams TM
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4795-8. PubMed ID: 17616394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.
    Lynch JJ; Regan CP; Edvinsson L; Hargreaves RJ; Kane SA
    J Cardiovasc Pharmacol; 2010 May; 55(5):518-21. PubMed ID: 20164785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.
    Burgey CS; Stump CA; Nguyen DN; Deng JZ; Quigley AG; Norton BR; Bell IM; Mosser SD; Salvatore CA; Rutledge RZ; Kane SA; Koblan KS; Vacca JP; Graham SL; Williams TM
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5052-6. PubMed ID: 16889959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis.
    Regan CP; Stump GL; Kane SA; Lynch JJ
    J Pharmacol Exp Ther; 2009 Feb; 328(2):571-8. PubMed ID: 18997059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.
    Doods H; Hallermayer G; Wu D; Entzeroth M; Rudolf K; Engel W; Eberlein W
    Br J Pharmacol; 2000 Feb; 129(3):420-3. PubMed ID: 10711339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
    Paone DV; Nguyen DN; Shaw AW; Burgey CS; Potteiger CM; Deng JZ; Mosser SD; Salvatore CA; Yu S; Roller S; Kane SA; Selnick HG; Vacca JP; Williams TM
    Bioorg Med Chem Lett; 2011 May; 21(9):2683-6. PubMed ID: 21251825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor.
    Boeglin D; Hamdan FF; Melendez RE; Cluzeau J; Laperriere A; Héroux M; Bouvier M; Lubell WD
    J Med Chem; 2007 Mar; 50(6):1401-8. PubMed ID: 17319653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.